Stocks and Investing Stocks and Investing
Fri, July 7, 2023
Thu, July 6, 2023
Wed, July 5, 2023
Mon, July 3, 2023

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $60 on, Jul 3rd, 2023


Published on 2024-10-28 04:37:41 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $66 to $60 on, Jul 3rd, 2023.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 2 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $25 on, Friday, May 26th, 2023
  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023


These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $40 on, Friday, June 30th, 2023
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $46 on, Tuesday, May 9th, 2023